Last reviewed · How we verify
Transient Multiple Daily Insulin Injections
Multiple daily insulin injections provide exogenous insulin to replace or supplement endogenous insulin production in diabetes management.
Multiple daily insulin injections provide exogenous insulin to replace or supplement endogenous insulin production in diabetes management. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (advanced or insulin-requiring).
At a glance
| Generic name | Transient Multiple Daily Insulin Injections |
|---|---|
| Also known as | MDI |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Insulin therapy |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a therapeutic regimen rather than a single drug entity, involving multiple subcutaneous insulin injections throughout the day to achieve glycemic control. The approach mimics physiological insulin secretion patterns by combining basal (long-acting) and bolus (rapid-acting) insulin doses with meals and correction doses. It is a standard insulin delivery method used in type 1 diabetes and advanced type 2 diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (advanced or insulin-requiring)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipohypertrophy
Key clinical trials
- Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: